Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 3, 2013, Pages 286-290

  Vickers, Andrew J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HUMAN; INFORMED CONSENT; LONGITUDINAL STUDY; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT INDICATION; UROLOGIST;

EID: 84875896012     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0040     Document Type: Review

References (23)

1. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009;56:753-760.
2. Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008;26:835-841.
3. Vickers AJ, Savage C, O'Brien MF, et al. A systematic review of pretreatment PSA velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.
4. Thompson IM, Ankerst D, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer PreventionTrial. J Natl Cancer Inst 2006;98:529-534.
5. Loeb S, Roehl KA, Catalona WJ, et al. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007;177:899-902.
6. O'Brien MF, Cronin AM, Fearn PA, et al. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer 2011;128:2373-2381.
7. O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27:3591-3597.
8. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-2816.
9. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99:526-532.
10. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-4305.
11. Vickers AJ, Wolters T, Savage CJ, et al. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. J Urol 2010;184:907-912.
12. Vickers AJ, Till C, Tangen CM, et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011;103:462-469.
13. Wolters T, Roobol MJ, Bangma CH, et al. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2009;55:385-392.
14. Auprich M, Augustin H, Budaus L, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int 2012;109:1627-1635.
15. Eggener SE, Yossepowitch O, Roehl KA, et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008;71:1016-1019.
16. Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011;185:126-131.
17. Kawachi MH, Bahnson RR, Barry M, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. J Natl Compr Canc Netw 2010;8:240-262. To view the most recent version of these guidelines, visit NCCN.org.
18. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527.
19. Loeb S, Metter EJ, Carter HB. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011;103:1636-1637; author reply 1637.
20. Loeb S, Metter EJ, Kan D, et al. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int 2012;109:508-513; discussion 513-514.
21. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-447.
22. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-135.
23. Khatami A, Aus G, Damber JE, et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170-174.